150 related articles for article (PubMed ID: 25143746)
1. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer.
Yin C; Jiang C; Liao F; Rong Y; Cai X; Guo G; Qiu H; Chen X; Zhang B; He W; Xia L
Onco Targets Ther; 2014; 7():1415-22. PubMed ID: 25143746
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy.
Jiang C; Liu S; He W; Zhang B; Xia L
J Cancer; 2017; 8(8):1410-1416. PubMed ID: 28638455
[No Abstract] [Full Text] [Related]
3. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer.
Yin C; Ma G; Rong Y; Kong P; Yang Q; Jiang C; Liao F; Zhang B; He W; Xia L
J Cancer; 2016; 7(13):1901-1906. PubMed ID: 27698931
[No Abstract] [Full Text] [Related]
5. Baseline serum lactate dehydrogenase level predicts survival benefit in patients with metastatic colorectal cancer receiving bevacizumab as first-line chemotherapy: a systematic review and meta-analysis of 7 studies and 1,219 patients.
Feng W; Wang Y; Zhu X
Ann Transl Med; 2019 Apr; 7(7):133. PubMed ID: 31157254
[TBL] [Abstract][Full Text] [Related]
6. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
Scartozzi M; Giampieri R; Maccaroni E; Del Prete M; Faloppi L; Bianconi M; Galizia E; Loretelli C; Belvederesi L; Bittoni A; Cascinu S
Br J Cancer; 2012 Feb; 106(5):799-804. PubMed ID: 22315053
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer.
Matsuhashi N; Takahashi T; Fujii H; Suetsugu T; Fukada M; Iwata Y; Tokumaru Y; Imai T; Mori R; Tanahashi T; Matsui S; Imai H; Tanaka Y; Yamaguchi K; Futamura M; Yoshida K
Mol Clin Oncol; 2019 Oct; 11(4):390-396. PubMed ID: 31475067
[TBL] [Abstract][Full Text] [Related]
8. Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis.
Quan Q; Huang Y; Chen Q; Qiu H; Hu Q; Rong Y; Li T; Xia L; Zhang B
Transl Oncol; 2017 Apr; 10(2):288-294. PubMed ID: 28292509
[TBL] [Abstract][Full Text] [Related]
9. Lactate Dehydrogenase Is a Useful Marker for Predicting the Efficacy of Bevacizumab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer.
Shibutani M; Maeda K; Kashiwagi S; Nagahara H; Fukuoka T; Iseki Y; Wang EN; Okazaki Y; Hirakawa K; Ohira M
Anticancer Res; 2021 Jul; 41(7):3535-3542. PubMed ID: 34230149
[TBL] [Abstract][Full Text] [Related]
10. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
Marmorino F; Salvatore L; Barbara C; Allegrini G; Antonuzzo L; Masi G; Loupakis F; Borelli B; Chiara S; Banzi MC; Miraglio E; Amoroso D; Dargenio F; Bonetti A; Martignetti A; Paris M; Tomcikova D; Boni L; Falcone A; Cremolini C
Br J Cancer; 2017 Jan; 116(3):318-323. PubMed ID: 28081548
[TBL] [Abstract][Full Text] [Related]
11. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.
Silvestris N; Scartozzi M; Graziano G; Santini D; Lorusso V; Maiello E; Barni S; Cinieri S; Loupakis F; Pisconti S; Brunetti AE; Palasciano G; Palmieri VO; Del Prete M; Dell'Aquila E; Latiano TP; Petrelli F; Lutrino S; Rossini D; Giampieri R; Lotesoriere C; Cascinu S
Expert Opin Biol Ther; 2015 Feb; 15(2):155-62. PubMed ID: 25411089
[TBL] [Abstract][Full Text] [Related]
12. The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
Bendell JC; Sauri T; Gracián AC; Alvarez R; López-López C; García-Alfonso P; Hussein M; Miron ML; Cervantes A; Montagut C; Vivas CS; Bessudo A; Plezia P; Moons V; Andel J; Bennouna J; van der Westhuizen A; Samuel L; Rossomanno S; Boetsch C; Lahr A; Franjkovic I; Heil F; Lechner K; Krieter O; Hurwitz H;
Oncologist; 2020 Mar; 25(3):e451-e459. PubMed ID: 32162804
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC.
Li B; Li C; Guo M; Shang S; Li X; Xie P; Sun X; Yu J; Wang L
Onco Targets Ther; 2018; 11():6287-6294. PubMed ID: 30310292
[TBL] [Abstract][Full Text] [Related]
14. Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer.
Jiang C; Huang YH; Lu JB; Yang YZ; Rao HL; Zhang B; He WZ; Xia LP
Cancer Manag Res; 2018; 10():3589-3597. PubMed ID: 30271207
[TBL] [Abstract][Full Text] [Related]
15. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab.
Uysal M; Bozcuk H; Sezgin Göksu S; Murat Tatli A; Arslan D; Gündüz S; Senol Coskun H; Ozdogan M; Savas B
Biomed Pharmacother; 2014 May; 68(4):409-12. PubMed ID: 24721326
[TBL] [Abstract][Full Text] [Related]
16. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
17. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
Artaç M; Coşkun HŞ; Dane F; Karabulut B; Korkmaz L; Karaağaç M; Çabuk D; Karabulut S; Faruk Aykan N; Doruk H; Avcı N; Turhal NS
J Gastrointest Cancer; 2016 Sep; 47(3):264-72. PubMed ID: 27126591
[TBL] [Abstract][Full Text] [Related]
18. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
[TBL] [Abstract][Full Text] [Related]
19. First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial.
Giampieri R; Puzzoni M; Daniele B; Ferrari D; Lonardi S; Zaniboni A; Cavanna L; Rosati G; Pella N; Zampino MG; Sozzi P; Germano D; Zagonel V; Codecà C; Libertini M; Labianca R; Cascinu S; ; Scartozzi M
Br J Cancer; 2017 Oct; 117(8):1099-1104. PubMed ID: 28926529
[TBL] [Abstract][Full Text] [Related]
20. Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.
van Dijk E; Biesma HD; Cordes M; Smeets D; Neerincx M; Das S; Eijk PP; Murphy V; Barat A; Bacon O; Prehn JHM; Betge J; Gaiser T; Fender B; Meijer GA; McNamara DA; Klinger R; Koopman M; Ebert MPA; Kay EW; Hennessey BT; Verheul HMW; Gallagher WM; O'Connor DP; Punt CJA; Loupakis F; Lambrechts D; Byrne AT; van Grieken NCT; Ylstra B
J Clin Oncol; 2018 Jul; 36(20):2052-2060. PubMed ID: 29792754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
